Corrections or additions?
These listings were published in U.S. 1 Newspaper on December 8,
1999. All rights reserved.
Biotech’s Vibrant Merry Go-Round: Part II
fax, 609-419-1092. Founded 1995. Paul McGarty, president. Staff size:
7. Square feet: 2,000.
Aesgen identifies, develops, and markets pharmaceutical products
generated by research conducted by the Mayo Clinic (U.S. 1, January
Cranbury 08152; 609-860-6640; fax, 609-860-7996. Founded 1993. William
O’Connor, vice president finance. Staff size: 25. Square feet:
Allelix works on neuroscience therapeutics, hoping to mitigate pain
caused by disorders of the brain and begin to treat such disorders
as depression and anxiety. With Janssen Pharmaceutica Allelix is also
working on treating schizophrenia and how to reduce neuropathic pain
that occurs when nerves are injured by cancer tumors, viral
or surgery Another area of research: Trying to reduce abnormal
that cause muscle spasms in those suffering from spinal cord injury,
multiple sclerosis, stroke, or cerebral palsy.
Funded by Healthcare Ventures and formerly known as Trophix
this lab is a division of Allelix Biopharmaceuticals in Toronto (U.S.
1, May 12, 1999).
Cranbury 08512; 609-655-5300; fax, 609-655-1755. Founded 1988. Mircea
C. Popescu, vice president, R&D. Staff size: 27. Square feet:
Biomira does research and development of protein-based liposomal
for cancer vaccines. For its parent company, it supervises the
of such products as a vaccine for small cell lung cancer. Well-known
scientist Larry Kwak is supervising the Phase I trials at the National
Cancer Institute for its patient-specific therapeutic cancer vaccine.
Biomira is also devising a clinical trial strategy for its liposomal
form of a cytokine, Interleukin 2. Owned by an Alberta-based firm,
it was formerly known as OncoTherapeutics Inc.
CN 5308, Princeton 08543-5308; 609-987-8200; fax, 609-452-2975.
1981. H. Joseph Reiser, CEO. Staff size: 48. Square feet: 31,000.
Cytogen makes and sells two imaging agents, ProstaScint for prostate
cancer patients and OncoScint for colorectal or ovarian cancer.
(licensed to Berlex) relieves cancer bone pain. Public since 1986,
the firm has more than 70,000 shares outstanding.
Cranbury, Box 7007, Princeton 08543-7007; 609-409-6080; fax,
Founded 1995. Jonathan W. Nyce, CEO. Staff size: 8. Square feet:
Epigenesis aims to be the leader in molecular therapeutics for
diseases. It does gene discovery, validates candidate targets for
drug discovery programs, and discovers and develops therapeutics for
medically important respiratory diseases. For target validation
uses desAdenosine RASON (respirable antisense oligonucelotides). It
has a proprietary model of human asthma and a library of novel genes
for the respiratory tract and central nervous system (U.S. 1, March
Jersey Avenue, New Brunswick 08901-3605; 732-249-3250; fax,
Founded 1980. Lawrence M. Gordon, CEO. Staff size: 40. Square feet:
Interferon studies, makes, and sells products based on highly
natural source, multispecies alpha interferon. Approved by the FDA
to treat certain types of genital warts, it is being studied for
treatment of HIV and hepatitis C.
Interferons are glycoproteins that contribute to the body’s natural
defenses against foreign substances. They bind to specified receptors
on cell surfaces. Though discovered in 1957, only in the last 15 years
could alpha interferons — derived from human white blood cells
— be manufactured cost effectively, and now the market for their
products is more than $1.5 billion worldwide. In contrast to more
widely available interferons, this company produces the only
available natural-source, multispecies alpha interferon in the United
It has three platform technologies: informatics, small molecule
chemistry, and high throughput screening. Also, its Molecular
software develops and commercializes molecular modeling simulations
and informatics software services. More than five million individual
small molecules — good for drugs administered by mouth rather
than by injection — have been synthesized.
The encoding technology (Encoded Combinatorial Libraries on Polymeric
Support, or ECLiPS) was invented in the early 1990s at Columbia and
Cold Spring Harbor. With other offices in San Diego, Cambridge, and
Tokyo, the firm has 550 employees. Inteferon Sciences has drug
collaborations with seven companies including Bristol-Myers Squibb,
Berlex, and Pharmacia & Upjohn. The firm went public in 1995 and is
covered by BT Alex. Brown, Cowen & Co., Evern Securities, Janney
Scott, Legg Mason, Lehman Brothers, and Punk Ziegel & Co.
Research Way, Princeton Forrestal Center, Princeton 08540-6619.
fax, 609-452-1890. Founded 1981. Charles A. Baker, CEO.
Liposome Company develops liposome- and lipid-based pharmaceuticals
to treat, prevent, and diagnose of inadequately treated,
diseases such as cancer. Lipids are the fatty substances that comprise
the membranes of all living cells, and the lipids themselves are
The firm has the leading lipid-based formulation of amphotericin B
in the United States and one marketed product, Abelcet, to treat
fungal infections. It also has such products in the pipeline as
TLC Ell-12, and bromotaxane for treatment of various cancers, and
is developing vehicles for the delivery of gene therapy.
Gateway, Suite 206, Princeton 08540; 609-430-2880; fax, 609-430-2850.
Founded 1987. Donald L. Drakeman, president.
Medarex develops and makes therapeutic products, especially bispecific
antibodies, Medarex and its partners are using the patented
technology to create fully human antibodies as novel therapies for
life-threatening and debilitating diseases (U.S. 1, November 17).
Medarex has seven of its own products in clinical trials, including
one in Phase III and five in Phase II. Four analysts cover the stock,
those from BT Alex Brown, Cruttenden Roth, Hambrecht & Quist, and
Miller Tabak Hirsch. More than 30 companies make a market in Medarex
stock; about 31.5 million shares are outstanding, and the average
daily trading volume is 125,000.
Robbinsville 08691; 609-208-9688; fax, 609-208-1868. Founded 1987.
Joseph Mo, CEO. Staff size: 6. Square feet: 6,000.
NexMed develops topical creams for sexual dysfunction for men and
women (U.S. 1, September 15, 1999). Last week it announced that its
Femprox cream, for treating female sexual arousal disorder,
a positive effect on increasing blood flow to the clitoris and labia
in 18 subjects.
Suite 100, Princeton 08540; 609-520-1911; fax, 609-452-0880. Edward
Quilty, CEO. Staff size: 8. http://www.palatin.com.
Palatin develops and commercializes products and technologies for
diagnostic imaging, cancer therapy, and ethical development. It uses
proprietary monoclonal antibody radiolabeling and enabling peptide
platform technologies. One of its products, LeuTech, has finished
Phase 3 clinical trials and Palatin and its strategic marketing
(Mallinckrodt in St. Louis) are seeking marketing clearance from the
FDA. LeuTech can be used to confirm a case of appendicitis. Injected
intravenously, its monoclonal antibody binds to white blood cells,
accumulates at the site of the infection, and gives a bright clear
image on a gamma camera. LeuTech is also being used to detect
If Palatin’s recently announced merger with Molecular Biosystems is
approved, the combined firms will keep the Palatin name and stay in
Princeton. It will then have one FDA approved product on the market
(Optison, for ultrasound imaging of the heart wall and cavity) and
products in the pipeline for a liver-selective imaging agent and a
drug for sexual dysfunction.
Princeton Corporate Plaza, Suite 116, Monmouth Junction 08852;
fax, 732-274-0086. Founded 1997. Prabha Fernandes, CEO. Staff size:
34. Square feet: 12,000. http://www.smtherapeutics.com.
A drug development company (U.S. 1, November 19, 1997).
Road, East Windsor 08520; 609-448-8200; fax, 609-448-8299. Founded
1997. Barry Wolitzky, vice president of discovery. Staff size: 50.
Coelacanth (pronounced see-la-kanth), came to the facility built by
PA Technologies last November and is moving from being a combinatorial
chemistry firm to doing drug development (U.S. 1, November 18, 1998).
It researches and develops "combinatorial libraries," or
bases of modular and chemical reactions that can help develop and
market new drugs. With a variety of high performance chemistry
it also does drug discovery in partnership with its clients —
major pharmaceutical companies and biotechs in the United States,
Europe, and Japan.
Princeton Corporate Plaza, Suite 210, Princeton 08540; 732-438-8001;
fax, 732-438-8004. Founded 1994. Staff size: 3. Square feet: 1,000.
ComGenex does combinatorial chemistry for pharmaceutical and
It produces new organic compounds and small organic molecules, and
it provides laboratory services. The U.S. headquarters is in San
8 Cedar Brook Drive, Cedar Brook Corporate Center, Cranbury 08512;
609-655-6900; fax, 609-655-6930. Founded 1992. Barbara Schilberg,
executive vice president. Staff size: 17. Square feet: 33,000.
Just announced: this antibacterial drug discovery lab is going to
be sold for more than $10 million in cash and some future milestone
payments. The buyer, though undisclosed, could very well be Merck.
Last August Merck made a milestone payment of $1.5 million, with
going to Princeton University, and $1 million to Incara, for research
on an antibiotic of last resort — a look alike to the powerful
vancomycin, perhaps able to combat increasingly resistant
or "superbugs." In various models Merck was able to synthesize
the firm’s specified compounds of new antibiotics and to prove that
they don’t damage the host.
Founded by Princeton University’s Daniel Kahne as Transcell
and more recently known as Intercardia Research Laboratories,
in this lab quit working on random combinatorial libraries in favor
of more targeted research on three other anti-infective programs (U.S.
1, August 11).
"We believe the purchaser of the antibacterial division has the
resources and complementary skills to fulfill the programs
says Clayton I. Duncan, president and CEO of Research Triangle-based
Incara Pharmaceuticals Corporation. "We have decided to focus
our resources on our three later stage programs."
Princeton 08543-5350; 609-452-3600; fax, 609-452-3672. Founded 1993.
Joseph A. Mollica, CEO. Staff size: 200. Square feet: 70,000.
Pharmacopeia offers patented chemical screening libraries for early
drug testing and development. Pharmacopeia is a leader in the field
of drug discovery using small molecule combinatorial chemistry,
and synthesizing large, diverse collections of compounds for
Current drug discovery collaborations are with Akzo Nobel/NV Organon,
Bayer Corporation, Berlex Laboratories, Daiichi Pharmaceutical
Novartis, Schering-Plough, Zeneca, and a research partnership with
Corporate Plaza, Suite 114, Monmouth Junction 08852; 732-329-8999;
fax, 732-329-8988. Founded 1995. Adam Yuan, president. Staff size:
7. Square feet: 2,300. http://www.tygersci.com.
This firm does custom synthesis and contract research for chemicals
Miles A. Libbey III, president. 732-656-0300; fax, 732-656-1344.
DelRx hopes to make life easier for diabetics with a mouth spray for
delivering insulin. Bill Williams, formerly of Rhone Poulenc Rorer,
is working at the University of Texas on this spray that would coat
the mucus membrane on the inside of the patient’s mouth. The firm
needs capital to get through Phase I clinical trials. Founded by Miles
A. Libbey III, Randall McCoy, and Sally and Bill Williams, DelRx is
a sister company to MQS Inc, which helps develop products for major
pharmaceutical and medical device companies.
08540; 609-720-0033; fax, 609-520-6692. Founded 1997. Martyn
CEO. Staff size: 51. http://www.delsyspharma.com.
Delsys develops automated drug manufacturing and drug delivery systems
through electrostatic dry powder deposition — the same technology
used in xerography and laser printers.
Privately held, it was founded at Sarnoff in 1995. With an initial
$6 million from Healthcare Ventures it spun off to be independent
and moved to College Road and at Princeton Corporate Plaza (U.S. 1,
September 17, 1997). It has collaborations with SmithKline Beacham,
GlaxoWellcome, Warner Lambert, Elan Corporation, and Johnson &
and recently had private placement funding of $14.5 million.
609-291-8683; fax, 609-291-1997. Founded 1987. John J. Wille,
Hy-Gene is a tissue engineering and biomedical products firm working
on skin protection and steroid antiinflammatories. Under a Phase I
small business innovation grant (SBIR) from the federal agriculture
department, Hy-Gene is doing feasibility studies on Derm-Care, a
non-separable oil-in-water emulsion technology for skin and wound
care. It is being examined for use in skin protection, skin
and as part of a drug delivery system for over-the-counter steroid
anti-inflammatories. An autologous cloned skin product, Autoderm,
was developed to treat non-healing wounds and has successfully
a prospective randomized clinical trial.
Monmouth Junction 08852; 732-329-2401; fax, 732-329-8502. Founded
1995. Anand V. Gumaste, CEO. Staff size: 12. Square feet: 6,000.
Formerly Advanced Medical Systems, MicroDose develops pulmonary, oral,
and transdermal drug delivery systems. On November 30 the privately
held company announced a joint venture with Quadrant Healthcare, a
public drug delivery company based in the United Kingdom, to develop
and exploit the pulmonary delivery of peptides and proteins. MicroDose
has patented "the next generation in inhaler technology,"
the totally electronic dry powder inhaler (DPI) and an electrostatic
deposition system (MEDS) to fill the unit doses for the DPI.
08901; 732-448-1515; fax, 908-218-0452. Kishore Shah, president. Staff
Polytherapeutics develops medical devices and drug delivery systems
and vaginal pharmaceutical products. Privately owned, PTI has a
office at 568 Cabot Hill Road in Bridgewater and a research lab on
Jersey Avenue. The R&D mission is to work on high value-added, patent
protected technologies and products in the field of polymer-based
medical devices and controlled release drug delivery systems. Three
U.S. patents and two pending international patent applications protect
its two platform technologies.
One is a drug delivery system for providing drugs over an extended
period of time at mucosal sites of the body, such as the vagina and
the eye. PTI is developing a long-acting microbicidal product for
intravaginal administration for preventing sexually transmitted
such as AIDs.
Princeton 08540; 609-514-7200; fax, 609-514-7219. Founded 1993. Jim
Wavle, CEO. Staff size: 42. http://www.therics.com.
Therics makes medical products using TheriForm, a fabrication process
with three-dimensional printing. Therics has an exclusive license
for a process patented by MIT for dry powder deposition to develop
it for all medical applications. "The technology is useful to
make dosage forms with unique characteristics and can also be in
engineering," says Jim Kindschi, vice president of strategic
"In contrast to Delsys, which uses electrostatic depositing, we
create three dimensional image on a computer screen and convert that
to a three dimensional construct."
A maker of plastic film (for diaper liners), Tredegar had owned
of Therics and recently bought the rest, so Therics is a wholly-owned
subsidiary of the Richmond, Virginia-based firm.
Princeton 08540; 609-466-8712; fax, 609-520-1702. Founded 1996. James
Pachence, president. Staff size: 5.
Veritas Medical does research and development of pharmaceutical
for sustained drug release.
Corrections or additions?
This page is published by PrincetonInfo.com
— the web site for U.S. 1 Newspaper in Princeton, New Jersey.